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Filaggrin Mutations Are Genetic Modifying Factors
Exacerbating X-Linked Ichthyosis
Haihui Liao1, Alex J. Waters2, David R. Goudie3, David A. Aitken4, Gordon Graham4, Frances J. D. Smith1,
Sue Lewis-Jones2 and W. H. Irwin McLean1
Mutations inactivating the STS gene cause X-linked ichthyosis (XLI), whereas null mutations in the FLG gene
cause ichthyosis vulgaris. Two brothers presented with XLI. One had a typical fine scaling, and the other was
much more severely affected. Both patients carried STS missense mutation T165I. Furthermore, the more
severely affected patient also carried heterozygous FLG mutation R501X, which was absent from his mildly
affected brother. These data suggest that disrupting epidermal differentiation via different pathways can
increase phenotypic severity. Owing to the high population frequency of FLG mutations, filaggrin is a possible
genetic modifier in other genodermatoses.
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INTRODUCTION
The two inherited disorders of keratinization most commonly
encountered by dermatologists are X-linked ichthyosis (XLI;
OMIM No. 308100) and ichthyosis vulgaris (IV; OMIM No.
146700) (Judge et al., 2004). The steroid sulfatase gene, STS,
located on the X chromosome, causing XLI, was the first
keratinizing disorder gene to be identified (Ballabio et al.,
1987; Bonifas et al., 1987; Gillard et al., 1987). A genomic
deletion involving the entire gene, which is readily detectable
by fluorescent in situ hybridization, appears to be the most
common cause of XLI in the human population (Bonifas et al.,
1987); however, less frequent point mutations in STS have
also been described (Basler et al., 1992; Alperin and Shapiro,
1997; Morita et al., 1997; Sugawara et al., 2000, 2001;
Valdes-Flores et al., 2000, 2001; Ghosh, 2004; Gonzalez-
Huerta et al., 2006). Very recently, loss-of-function mutations
in the gene encoding filaggrin (FLG) have been shown to
underlie IV, which is inherited as a semidominant Mendelian
trait where heterozygotes may have a mild sub-clinical
presentation compared with homozygotes who present with
marked scaling (Sandilands et al., 2006; Smith et al., 2006;
Gruber et al., 2007). Hyperlinearity of the palms appears to
be a useful clinical diagnostic indicator for IV (Sandilands
et al., 2006; Smith et al., 2006). Two FLG mutations, R501X
and 2282del4, both leading to loss of filaggrin expression, are
common in European origin populations (Smith et al., 2006);
however, several other rare and prevalent mutations are
emerging, including mutations specific to Asian populations
(Nomura et al., 2007; Sandilands et al., 2007). We recently
showed that filaggrin loss-of-function mutations also predis-
pose individuals to atopic dermatitis and related allergic
diseases (Palmer et al., 2006). This has been extensively
replicated in European populations, as reviewed recently
(Irvine and McLean, 2006; Irvine, 2007).
Here we report on a family in which the phenotypic
consequences of genetic interaction between STS and FLG
mutations were observed.
CASE REPORT
The proband was a 9 year-old Scottish boy, who, like his 6
year-old maternal half-brother, has suffered from ichthyosis
since early infancy. A half-sister is unaffected. The fathers of
the two boys are clinically unaffected, but the mother has dry
skin and subtle signs of IV, including hyperlinearity of the
palms (Figure S1). Anamnestically, the mother’s nephew and
maternal grandfather were affected with similar conditions.
There are no known females affected by overt signs ichthyosis
within the family.
The two half-brothers were both born following prolonged
labors (as is commonly seen with XLI neonates), but a
collodion membrane was not noted for either child. The
younger brother has clinical features consistent with XLI, with
fine dry scaling of the limbs and trunk, relative sparing of the
flexures, and sparing of the palms and soles (Figure 1a and b).
He also has mild atopic dermatitis, and his combined skin
conditions have responded well to emollients and medium-
potent topical corticosteroids. He has not required systemic
therapy for his skin.
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The older brother (proband) has a similar distribution of
ichthyotic skin, but with a severity that is unusual for XLI. In
all affected areas, the degree of hyperkeratosis is much
greater than seen in his younger brother. Large polygonal
scales are present on his limbs, with areas of ridged
hyperkeratosis around his elbows and knees (Figure 1c and
d), that are reminiscent of bullous congenital ichthyosiform
erythroderma (OMIM No. 113800; also known as epidermo-
lytic hyperkeratosis) or more severe cases of ichthyosis
bullosa of Siemens (OMIM No. 146800). He has marked
hyperlinearity of his palms, a feature which is not present in
his younger sibling. Further clinical images are available as
Figure S1.
The older brother’s ichthyosis was initially managed with
emollients alone, but following a progressive deterioration of
his skin condition he was commenced on systemic acitretin
therapy at the age of 8 years. This has resulted in a significant
partial improvement to his skin, although he remains much
more severely affected than his younger brother.
RESULTS AND DISCUSSION
White cell steroid sulfatase activity in the younger of the two
brothers was found to be 0 pmol/hour/mg protein, consistent
with the initial diagnosis of XLI (mean male control¼103.7,
standard deviation¼25.3). The common STS genomic
deletion was sought in the two affected patients by
fluorescent in situ hybridization, which showed that the gene
was present in both patients (data not shown), implying the
presence of a small insertion/deletion undetectable by
fluorescent in situ hybridization, or a point mutation. The
STS gene was fully analyzed by PCR and sequencing of
the individual exons. One hemizygous point mutation
(c.494T4C) in exon 5 of STS was detected in both patients
(Figure 2a and b), which results in the amino-acid change
threonine to isoleucine at codon 165 (standard protein
mutation designation p.Thr165Ile, or abbreviation T165I).
Since the T165I mutation had not been reported previously, it
was excluded from 80 normal controls (50 female and 30
male, i.e., 130 normal X chromosomes) by Bcl I restriction
digestion (Figure 2c). This threonine residue is highly
conserved in mammalian aryl sulfatases (Figure S2), consis-
tent with the loss of enzyme activity observed here. The
mother was found to be a heterozygous carrier of this
mutation, consistent with X-linked recessive inheritance. The
two patients were also analyzed for the common FLG
loss-of-function mutations, R501X and 2282del4, using
established methods (Smith et al., 2006). The more severely
affected brother was found to be a heterozygous carrier of
R501X, whereas the mildly affected brother did not carry
either mutation (Figure 2d). The mother was a heterozygous
carrier of R501X consistent with her palmar hyperlinearity
and mild features of IV (data not shown). Thus, the complete
absence of steroid sulfatase activity in addition to a
heterozygous nonsense mutation in FLG correlated with
the more severe ichthyosis–hyperkeratosis phenotype observed
in the family, suggestive of pathogenic synergy between these
genes.
Arylsulfatase C isoform S, encoded by the STS gene, is a
key enzyme involved in the biosynthesis of lipid species that
are essential for the formation and maintenance of the
cornified cell envelope, which is an important structural
component of the stratum corneum (Elias et al., 2004). Lack
of STS enzyme activity during late epidermal differentiation
leads to impairment of stratum corneum formation and skin
barrier function, which manifests clinically as the xerosis and
scaling seen in XLI. Two parallel pathogenic mechanisms
have been suggested whereby STS deficiency leads to
ichthyosis: (a) interference of accumulated STS substrate
cholesterol sulfate (CSO4) in the stratum corneum with
lamellar phase separation and (b) inhibition of corneodesmo-
some degradation by CSO4, which has serine protease
inhibitory activity, leading to reduced desquamation and
retention hyperkeratosis (Elias et al., 2004). The FLG gene
encodes the giant inactive precursor protein profilaggrin,
which is the main constituent of keratohyalin granules in the
stratum granulosum (Listwan and Rothnagel, 2004). Upon
terminal differentiation of granular cells, profilaggrin is
proteolytically cleaved into multiple copies of the func-
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Figure 1. Clinical characteristics of the XLI patients. (a and b) Clinical
appearance of the younger brother showing dry fine scaling around the
(a) elbow and (b) knee. (c and d) Clinical characteristics of the older brother
showing marked hyperkeratosis, with ridged hyperkeratosis around the elbow
and knees. These photographs were taken after several months of acitretin
therapy; the previous clinical appearance had been even more severe. Further
clinical pictures of these individuals are available as Figure S1.
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tional filaggrin peptide. This is thought to have two main
functions: condensation of the keratin cytoskeleton, which
may contribute to squame formation (Steinert et al., 1981)
and acting as a source of hygroscopic amino acids and
derivatives thereof to aid stratum corneum hydration
(Rawlings and Harding, 2004). The filaggrin linker peptide
has also been identified in transglutaminase cross-linked
components of the cornified cell envelope and may therefore
also have a purely structural role within the stratum corneum
(Takahashi et al., 1996). Thus, these two genes involved
in clinically distinct ichthyoses act via separate pathways
within the lipid and protein biochemistry of stratum
corneum biogenesis, consistent with the additive patho-
genic effects seen in the patient carrying both mutations
(Figure 1).
Filaggrin mutations were recently shown to be strongly
associated with atopic dermatitis (Irvine, 2007; Sandilands
et al., 2007). Interestingly, the boy here who did not carry the
FLG mutation had atopic dermatitis, whereas the brother with
both FLG and STS mutations did not. The penetrance of
eczema in heterozygous FLG carriers is estimated at 60%
(McLean, unpublished data). Since only 50% of children with
moderate-severe atopic dermatitis in European populations
carry FLG mutations, there are obviously other genes involved
in the pathogenesis of this complex disease. What we observe
here may involve an effect of the small numbers (n¼1 for
each STS/FLG genotype), the incomplete penetrance of FLG
with respect to atopic dermatitis, or the action other unknown
atopic dermatitis genes. A larger study of the interactions
between FLG, STS, and eczema will reveal if STS mutations
could be protective for filaggrin-related atopic dermatitis.
Phenotypic variation is commonly reported in a number of
inherited disorders of keratins, including bullous congenital
ichthyosiform erythroderma/epidermolytic hyperkeratosis,
ichthyosis bullosa of Siemens, and pachyonychia congenita,
where individuals within and between families have been
shown to present with either mild or severe phenotypes despite
carrying the same keratin mutation (McLean et al., 1994;
Rothnagel et al., 1994; Covello et al., 1998; Smith et al.,
1998). In one case, a non-synonymous polymorphism in K5
inherited in trans with a dominant-negative K5 mutation was
shown to exacerbate the skin blistering phenotype in a kindred
with epidermolysis bullosa simplex (Yasukawa et al., 2002);
however, in most cases, the molecular mechanism(s) under-
lying phenotypic variation in this group of diseases remains
unknown. Here, we show that co-inheritance of both STS and
FLG mutations appears to increase ichthyosis disease severity.
Owing to the high frequency of FLG mutations in the popu-
lation, which can be as common as 9% of European origin
people (Palmer et al., 2006; Smith et al., 2006), filaggrin
should be considered as a possible genetic modifying factor in
other genodermatoses. In particular, FLG might be considered
as a modifying gene in those disorders of keratinization affe-
cting the upper suprabasal keratinocyte compartments of the
epidermis where there are known to be genetic defects in path-
ways complementary to filaggrin, as is the case here with STS.
MATERIALS AND METHODS
DNA samples were collected with Institutional Research Ethics
Committee approval and informed consent that complies with the
Declaration of Helsinki Principles.
The radiometric assay of steroid sulfatase activity utilizing the
natural substrate dehydroepiandrosterone sulfate was performed as
described previously (Gillard et al., 1987). This was modified for use
with leukocytes isolated from EDTA-treated blood.
Fluorescent in situ hybridization analysis for the STS gene was
performed using the Vysis LSI Steroid Sulfatase Microdeletion probe
in combination with the Vysis CEPX control probe for the X
chromosome (Abbott Laboratories Ltd, Maidenhead, UK), according
to the manufacturer’s recommended protocol.
The primers used for PCR amplification and sequencing of all
exons of the STS gene are listed in Table S1 on line. PCR reactions
(25 ml) consisted of 200 ng of genomic DNA template, 0.5 mM
Normal STS codons 163–167 Bcl I screening for STS T165I
Nla III screening for FLG R501XXLI patient, STS mutation T165I
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Figure 2. Molecular genetic analysis of STS and FLG genes. (a, b) Direct DNA
sequencing of exonic PCR products derived from the STS gene revealed a
missense mutation in the affected individuals. (a) Normal control sequence,
showing codons 163-167 of the STS gene. (b) The same region of the STS gene
shown in (a), derived from the proband, showing hemizygous mutation
c.494T4C, predicting amino-acid substitution T165I in the steroid sulfatase
polypeptide. The hemizygous mutation was found to be present in both
affected brothers and was also carried heterozygously by their unaffected
carrier mother (sequence data not shown). (c) Confirmation of STS mutation
T165I in the proband and his affected brother by Bcl I digestion of STS PCR
products, where this mutation was shown to create a new Bcl I restriction site
not present in normal controls. The heterozygous mutation was similarly
confirmed in the carrier mother (data not shown). (d) Identification of the
R501X mutation in FLG. This mutation creates a new Nla III restriction site,
which can be used for rapid screening, as previously described (Smith et al.,
2006). The severely affected brother (proband) carries this filaggrin mutation,
as does an unrelated known carrier of R501X used as a positive control. In
contrast, the mildly affected brother does not carry the filaggrin mutation as
shown by the normal digestion pattern. Thus, the presence of both the
STS-inactivating missense mutation and a loss-of-function FLG mutation
correlates with marked disease severity.
www.jidonline.org 2797
H Liao et al.
Filaggrin as a Genetic Modifier
primers, 4% DMSO, 0.25 mM deoxynucleotide triphosphate, and 1 U
Taq polymerase in 1 GeneAmp PCR Buffer II containing 1.5 mM
MgCl2 (Roche Diagnostics, Burgess Hill, UK). The PCR program used
for STS exons 1, 2, and 6–9 was as follows: 941C for 5 minutes; 30
cycles of 941C for 30 seconds, 571C for 1 minute, 721C for 2 minutes;
a final extension of 721C for 5 minutes. For exons 3 and 4, an
annealing temperature of 521C was used; for exon 10, an annealing
temperature of 551C was used.
Screening for the common mutations R501X and 2282del4 in
exon 3 of FLG was performed by Nla III restriction enzyme digest
and confirmed by DNA sequencing, according to the published
methods (Smith et al., 2006).
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